Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis

Table 1 Serum measurements in control and fibrotic mice

	Control	CCl4 only	Rosi	Rln	Rosi + Rln
Body weight (g)	26.7 ± 0.9	25.6 ± 0.8	24.8 ± 1.0	24.9 ± 1.0	24.7 ± 0.9
Liver weight (g)	1.7 ± 0.1	1.7 ± 0.1	1.5 ± 0.1	1.6 ± 0.1	1.4 ± 0.1
Liver (% body wt)	6.3 ± 0.1	6.7 ± 0.3	6.1 ± 0.3	6.4 ± 0.4	5.8 ± 0.2
ALT	91.8 ± 5.7	2656 ± 538a	3892 ± 676a	1755 ± 610ab	3227 ± 313a
AST	368 ± 33	1621 ± 282a	2496 ± 339a	1278 ± 277ab	1863 ± 165a
Human relaxin (ng/mL)	ND	ND	ND	28.6 ± 7.2	20.5 ± 7.4
Adiponectin (ug/mL)	35.0 ± 3.4	32.6 ± 3.9	86.0 ± 12.2c	32.4 ± 2.2	147.5 ± 18.7c

^aP < 0.05 vs control;

^bP < 0.05 vs rosiglitazone (Rosi);

^cP< 0.05 vs control, CCl₄ only or relaxin (Rln). ND: Not detected.